Ignacio Martinez

Novomer, Inc. is a leading developer of chemical conversion technology to address market needs for transformable, functional, and high carbon utility materials. Novomer’s current focus is in the development of beta-propiolactones and derivatives, using its proprietary Novo22™ catalyst. Our patented technology focuses on catalyst, process conversion, and polymerization techniques to provide chemical intermediates, compostable polymers, and high-performance functionalized lactones. Novomer’s investment base includes strategic investors Saudi Aramco, SABIC and DSM and financial investors Flagship Ventures, OVP Ventures, and Physic Ventures. For more information, visit www.novomer.com.

Indigo Ag improves farmer profitability, environmental sustainability, and consumer health through the use of nature-based and digital technologies. The company’s core solutions – Sustainability and Biologicals – integrate across the supply chain to optimize how the world’s most impactful crops are produced, sourced, and distributed. Founded in 2013 with a mission of harnessing nature to help farmers sustainably feed the planet, today the companys technology connects stakeholders across the agricultural ecosystem to unlock sustainability and profitability benefits for all.

The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making. Our Solutions We offer a versatile portfolio of proprietary proteomics services, software, and kits. We make these widely available for pharmaceutical and biotechnology researchers and proteomics experts. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all major sample types – cells, tissues, or body fluids – across human and non-human species. Our Technology Biognosys is the leading inventor and developer of mass spectrometry-based proteomics solutions. With market leading proteome coverage and sample throughput we enable simultaneous quantification of thousands of proteins across thousands of samples. Our Facility From our global headquarters just outside of Zurich, we operate one of the largest high-end mass spectrometry laboratories worldwide for Large-Scale Discovery Proteomics contract research. Our Data Competence Biognosys has analyzed a vast amount of proteomics data and developed an industry-leading understanding of the proteome. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. Global Presence Founded in 2008 as a spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys today is an established leader in next-generation proteomics. With employees based across Switzerland, Europe, and US, and an extensive network of collaborators and distributors, Biognosys supports a global customer base of life science researchers across industry and academia.

Founded in 2006 as a spin out from the University of Leeds, Chamelic is a technology based surface treatment company. Chamelic has the RepelSmart surface treatments targeted at the Soalr Energy market. The products improve efficiency by keeping the surfaces of solar panels and mirrors clean.

YourBio Health is an innovative medical device company advancing a disruptive, cutting-edge approach to the way we draw blood. YourBio Health (formerly SeventhSense Biosystems) designed and developed TAP®, the world’s first push-button blood collection device that makes the blood process simple, convenient, and more comfortable. Patients go to the doctor more than 1 billion times a year to have their blood drawn with a needle, which requires an in-person interaction and often causes anxiety and discomfort for the patient. Now, patients can simply place the TAP device on their upper arm and begin collecting blood with the press of a button. This innovation is a game-changer for the health care system and will improve patients’ lives.

World-class RNA expertise to tackle the food and agriculture system’s greatest challenges

Montai Health is focused on unlocking the power of nature to create Anthromolecule™ medicines that treat and preempt a broad range of human diseases, with an initial focus on inflammatory and autoimmune diseases. Montai's CONECTA™ platform comprehensively maps Anthromolecule bioactivity across pathways that drive disease. The CONECTA platform leverages rapid and ever-growing advancements in the digitization of natural chemistry and human biology coupled with powerful computational tools for linking chemical structure and bioactivity. This confluence of biotechnologies enables Montai to build a powerful, one-of-a-kind discovery platform focused on creating safe, effective, and more human-centric medicines than ever before. Montai Health was founded in Flagship Labs in 2019. For more information, please visit www.montai.com.